How can pharma meet the need for new diabetes drugs in cash-strapped healthcare markets?
Experts will be discussing this issue in a Tweetchat, hosted by PMLiVE and M3, the global provider of technology services in healthcare. From noon to 1pm (UK time) you will be able to follow the discussion live on Twitter using the hashtag #M3diabetes and (should you want to) you are invited to join in with your own questions and comments.
Short-term intensive insulin therapy at diagnosis in type 2 diabetes
An expert workshop was convened to assess the available evidence and the potential application of STII therapy should it be advocated for inclusion in clinical practice (Diabetes/Metabolism Research and Reviews)
Targeting intensive versus conventional glycaemic control for type 1 diabetes mellitus
There was no significant effect towards improved all-cause mortality when targeting intensive glycaemic control compared with conventional glycaemic control. However, there may be beneficial effects of targeting intensive glycaemic control on the composite macrovascular outcome and on nephropathy, and detrimental effects on severe hypoglycaemia (BMJ Open)